CDK4/6 inhibitors in early breast cancer roundtable

Welcome to this roundtable with Sara Tolaney, Hope S. Rugo and Marc Thill. Join the faculty as they review current clinical data and guidelines, discuss optimal CDK4/6 inhibitor use in early breast cancer (EBC) and explore treatment options in people at high risk of recurrence.

Before watching the roundtable, please take a moment to evaluate your current level of knowledge on the topics covered by participating in this short quiz.

Please complete the following evaluation form

This short form consists of a post-roundtable multiple choice quiz, followed by a brief feedback form. It will take 5 minutes to complete. A certificate will be issued and sent to the email provided in your profile within 5 working days.

Roundtable agenda

Learning objectives

After participating in this educational activity, you will be able to:

• Describe the role of CDK4/6 inhibitors within the treatment landscape for HR+/HER2– early breast cancer (EBC)
• Identify differences in guideline recommendations for CDK4/6 inhibitor use in HR+/HER2– EBC
• Assess patients at high risk of recurrence and select the optimal treatment
• Recognise the current challenges for integrating CDK4/6 inhibitors approved for EBC into clinical practice

Faculty

Sara Tolaney, MD, MPH (Chair)

Dr Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute and is internationally recognised for her research and education leadership in breast cancer. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers, is a senior physician at Dana-Farber Cancer Institute, and Associate Professor of Medicine at Harvard Medical School.

Hope S. Rugo, MD, FASCO

Dr Hope S. Rugo, MD, FASCO, is a medical oncologist specialising in breast cancer research and treatment. Dr. Rugo is the Director of Breast Oncology and Clinical Trials Education at the UCSF Helen Diller Family Comprehensive Cancer Center. She is a principal investigator of multiple clinical trials focusing on novel targeted therapeutics to improve the treatment of breast cancer, publishing widely in this area.

Marc Thill, MD, PhD

Professor Dr Marc Thill MD. PhD, is director of the Department of Gynecology and Gynecologic Oncology, spokesperson of the Interdisciplinary Breast Cancer Center and head of the Gynecologic Cancer Center at the Agaplesion Markus Hospital in Frankfurt am Main, Germany.

Disclosures

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Sara Tolaney, MD, MPH – Grants/research support from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Gilead, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi and Seattle Genetics. Consultancy fees from 4D Pharm, Aadi Bioscience, ARC Therapeutics, Artios Biopharmaceuticals, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, CytomX, Incyte Corp, Menarini/Stemline, Myovant, OncXerna, Reveal Genomics, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen and Zymeworks.

Hope S. Rugo, MD, FASCO – Consultancy fees from for Daiichi Sankyo, Eisai, Mylan and Napo Pharmaceuticals. Grants/research support from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, GlaxoSmithKline, Lilly, Merck & Co, Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics, Taiho Oncology and Veru.

Marc Thill, MD, PhD – Advisory board or panel fees from Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Clearcut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal (relationship terminated), GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Pierre-Fabre, Roche, RTI Surgical (relationship terminated), Seagen, Sirius Medical and Sysmex. Consultancy fees from Daiichi Sankyo, Lilly, Neodynamics, pfm medical. Grants/research support from AstraZeneca, Clearcut, Exact Sciences, Neodynamics, Novartis, pfm medical, Roche and RTI Surgical. Speakers’ bureau fees from Amgen, Art Tempi, AstraZeneca, Clovis (relationship terminated), Connect Medica, Eisai, Exact Sciences, Gilead Science, GSK, I-Med-Institute, Jorg Eickeler, Laborarztpraxis Walther et al., Lilly, Medscape, Medtronic (relationship terminated), MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Sysmex, Viatris and Vifor Pharma. Other financial or material support from Amgen, AstraZeneca, Clearcut, Clovis (relationship terminated), Connect Medica, Daiichi Sankyo, Daiichi Sanyko, Eisai, Exact Sciences, Gilead, Hexal, Hexal, Lilly, MSD, Neodynamics, Neodynamics, Novartis, Novartis, Pfizer, Pfizer, pfm medical, pfm Medical, Roche, Roche, Roche, RTI Surgical, Seagen, Servier and Sirius Medical.

USF Health adheres to the Standards for Integrity and Independence in Accredited Continuing Education. All individuals in a position to influence content have disclosed to USF Health any financial relationship with an ineligible organization. USF Health has reviewed and mitigated all relevant financial relationships related to the content of the activity. The relevant financial relationships are listed below. All individuals not listed have no relevant financial relationships.

Sara Tolaney, MD, MPH – Grants/research support from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Daiichi Sankyo, Eisai, Eli Lilly, Exelixis, Genentech/Roche, Gilead, Merck, Nanostring, Novartis, OncoPep, Pfizer, Sanofi and Seattle Genetics. Consultancy fees from 4D Pharm, Aadi Bioscience, ARC Therapeutics, Artios Biopharmaceuticals, Bayer, BeyondSpring Pharmaceuticals, Blueprint Medicines, CytomX, Incyte Corp, Menarini/Stemline, Myovant, OncXerna, Reveal Genomics, Umoja Biopharma, Zentalis Pharmaceuticals, Zetagen and Zymeworks.

Hope S. Rugo, MD, FASCO – Consultancy fees from for Daiichi Sankyo, Eisai, Mylan and Napo Pharmaceuticals. Grants/research support from Astellas Pharma Inc., AstraZeneca, Daiichi Sankyo, F. Hoffmann-La Roche AG/Genentech, Gilead Sciences, GlaxoSmithKline, Lilly, Merck & Co, Novartis, OBI Pharma, Pfizer, Pionyr Immunotherapeutics, Sermonix Pharmaceuticals, Stemline Therapeutics, Taiho Oncology and Veru.

Marc Thill, MD, PhD – Advisory board or panel fees from Agendia, Amgen, AstraZeneca, Aurikamed, Becton/Dickinson, Clearcut, Clovis, Daiichi Sankyo, Eisai, Exact Sciences, Gilead Science, Grünenthal (relationship terminated), GSK, Lilly, MSD, Neodynamics, Novartis, Onkowissen, Organon, Pfizer, pfm medical, Pierre-Fabre, Roche, RTI Surgical (relationship terminated), Seagen, Sirius Medical and Sysmex. Consultancy fees from Daiichi Sankyo, Lilly, Neodynamics, pfm medical. Grants/research support from AstraZeneca, Clearcut, Exact Sciences, Neodynamics, Novartis, pfm medical, Roche and RTI Surgical. Speakers’ bureau fees from Amgen, Art Tempi, AstraZeneca, Clovis (relationship terminated), Connect Medica, Eisai, Exact Sciences, Gilead Science, GSK, I-Med-Institute, Jorg Eickeler, Laborarztpraxis Walther et al., Lilly, Medscape, Medtronic (relationship terminated), MSD, Novartis, Onkowissen, Pfizer, pfm medical, Roche, Seagen, Sysmex, Viatris and Vifor Pharma. Other financial or material support from Amgen, AstraZeneca, Clearcut, Clovis (relationship terminated), Connect Medica, Daiichi Sankyo, Daiichi Sanyko, Eisai, Exact Sciences, Gilead, Hexal, Hexal, Lilly, MSD, Neodynamics, Neodynamics, Novartis, Novartis, Pfizer, Pfizer, pfm medical, pfm Medical, Roche, Roche, Roche, RTI Surgical, Seagen, Servier and Sirius Medical.